No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Cellectar Biosciences Enhances CEO and COO Severance Benefits
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Hold Rating
Cellectar Biosciences: Promising Future With FDA Clarity and Innovative Radiopharmaceutical Advancements
Oppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)
Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings
Earnings Call Summary | Cellectar BioSciences(CLRB.US) Q4 2024 Earnings Conference